20 November 2013
Australian Financial Review: Biotech sector revival as appetite for risk grows
Australian Financial Review Journalist, Bina Brown reported on an Australian equities market shift away from resources into biotech and included Starpharma as a company to watch. The article noted the recent positive data showing that the Company’s delivery technology can make commonly use cancer drugs work a lot better as well as reduce side effects that can result in patients having to stop treatment.
“[Starpharma’s] delivery technology can not only make commonly used cancer drugs work a lot better, but can get rid of the main side-effects that can mean cancer patients have to stop using them.. ‘If the human data is anything like what we have seen in preclinical studies, this will be a total game changer.’”